Search results for: 'companion diagnostics deals and alliance of 2017'

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report offers in-depth insights and exclusive access to clinical-stage partnering agreements signed by the world’s leading biopharma companies, providing a detailed analysis of deal structures, financial terms and strategic collaborations.

Track JV activity across pharma and biotech with real-world examples, financial terms, and partnering trends—includes access to contract documents where available.

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report offers in-depth insights and exclusive access to preclinical-stage partnering agreements signed by the world’s leading biopharma companies, providing a detailed analysis of deal structures, financial terms and strategic collaborations.

Global Academic and Non-Profit Partnering Terms and Agreements 2019-2025 report provides a detailed understanding and analysis of how and why companies enter Academic and Non-Profit partnering deals. 

Licensing Deals in Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2019 to 2025

Global Biotech Partnering Terms and Agreements 2018 to 2023 report provides a detailed understanding and analysis of how and why companies enter biotech partnering deals.

Global Specialty Pharmaceutical Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter specialty pharmaceutical partnering deals. 

Central Nervous System (CNS) Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals | Comprehensive deal directory 2020 to 2025

Collaboration Deals in Pharmaceuticals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2020 to 2025

Provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals